Table 5.
Subgroup analysis of L/M.
| Subgroup by | Studies | Participants | MD (95% CI) | I2 | P | P for heterogeneity | |
|---|---|---|---|---|---|---|---|
| Country | Austria | 1 | 28 | -0.01[-0.02, 0.01] | NA | 0.42 | NA |
| Canada | 2 | 36 | -0.00 [-0.01, 0.01] | 45% | 0.67 | 0.18 | |
| China | 2 | 250 | -0.04[-0.05, -0.03] | 0% | <0.00001 | 0.36 | |
| India | 2 | 156 | -0.01 [-0.04, 0.01] | 3% | 0.34 | 0.31 | |
| Netherlands | 1 | 47 | 0.00 [-0.01, 0.01] | NA | 0.45 | NA | |
| Population characteristics | Critically ill patients | 1 | 14 | -0.00 [-0.01, 0.01] | NA | 0.66 | NA |
| Patients with migraine | 1 | 47 | 0.00 [-0.01, 0.01] | NA | 0.45 | NA | |
| Patients with metabolic syndrome | 1 | 28 | -0.01 [-0.02, 0.01] | NA | 0.42 | NA | |
| Patients with acute pancreatitis | 1 | 32 | 0.09 [-0.11, 0.29] | NA | 0.37 | NA | |
| Patients with gastrointestinal diseases | 4 | 396 | -0.04[-0.06, -0.02] | 60% | 0.0001 | 0.06 | |
| Age | <18 | 1 | 124 | -0.01 [-0.04, 0.01] | NA | 0.28 | NA |
| ≥18 | 7 | 393 | -0.02 [-0.04, 0.00] | 89% | 0.09 | <0.00001 | |
| Duration of treatment | < 2 weeks | 2 | 46 | 0.00 [-0.01, 0.01] | 0% | 0.69 | 0.36 |
| ≥2 weeks | 6 | 471 | -0.02 [-0.04, 0.00] | 90% | 0.07 | <0.00001 | |